This years’ BioProNET2 symposium will be virtual, covering the entire range of production and manufacture of biological modalities (expression-process-analytics). Presentations will be delivered in short sessions, starting at 14:00 on the afternoon of November 8th and finishing at 13:20 on November 9th.
Day 1 - Vaccines/viral vectors - November 8th, 14.00-15.20
Cath Green (Jenner Institute, University of Oxford) – Lessons learned from COVID 19 (title tbc)
Qasim Rafiq (UCL) - Process intensification and scalable manufacturing strategies for advanced therapies
Carol Knevelman (Oxford BioMedica) - Evolving approaches to viral vector manufacturing development
Day 1 - New avenues in bioprocessing - November 8th, 15.30-16.50
Natalie Howe (Evox Therapeutics)- Separation, Characterisation and enrichment of extracellular vesicles for therapeutic applications
Petra Hanga (UCL) - Bioprocess development for the production of cultivated meat
Yuval Elani (Imperial College London) - A toolkit for synthetic cell manufacture: microfluidics, biomembrane engineering, and synthetic biology
Day 2 - Products fit for function - November 9th, 09.00-10.20
Nico Callewaert (Ghent University, Belgium) - GlycoDelete glycans as chemo-orthogonal coupling sites to biopharmaceuticals
Ian Anderson (Pharmaron)- Innovative approaches to AAV analytics
Noel Smith (Lonza) How optimising the design of biotherapeutics can de-risk the development journey
Day 2 - Novel protein format therapeutics - November 9th, 10.30-11.50
Ashley Buckle (Monash University, Australia) Pre-stabilisation as a strategy for making robust monobodies
Dave Beal (University of Kent) - Protein Hydras: Enhancing the cytotoxic potential of antibody drug conjugates (ADC)?
Alex MacPherson (UCB) - Isolation of antigen-specific disulphide-rich knob domain peptides from bovine antibodies
Day 2 - Cell-free production/systems - November 9th, 12.00-13.20
Karen Polizzi (Imperial College London) - Development of a high-yield cell-free synthesis platform from Pichia pastoris
Colin Barker (BiologIC Technologies) - The Industry 4.0 Biocomputer; high density bio-processing to enable the syn-bio revolution
Trevor Hallam (Sutro Biopharma, US) -Development of CF engineering and production methods for the design and cGMP manufacture of advanced complex biologic oncology therapeutics
BioProNET2 Steering Group: Paul Dalby (UCL), Alan Dickson (University of Manchester), Jo Flannelly (University of Manchester), Cleo Kontoravdi (Imperial College), Mark Smales (University of Kent), Ivan Wall (Aston University).
The steering group includes representatives of AstraZeneca, Cell & Gene Therapy Catapult, Cobra Biologics, Fujifilm Diosynth Biotechnologies, GSK, Kymab, Lonza Biologics, Pharmaron, Pall Corporation and UCB